PT  - JOURNAL ARTICLE
AU  - Pitas, Katrina
AU  - Piefer, Greg
TI  - SHINE technology and progress toward U.S.-based molybdenum-99 production.
DP  - 2015 May 01
TA  - Journal of Nuclear Medicine
PG  - 165--165
VI  - 56
IP  - supplement 3
4099  - http://jnm.snmjournals.org/content/56/supplement_3/165.short
4100  - http://jnm.snmjournals.org/content/56/supplement_3/165.full
SO  - J Nucl Med2015 May 01; 56
AB  - 165 Objectives SHINE Medical will end medical isotope shortages using its LEU-fission-based production technology.Methods A beam-target neutron generator drives fission in a subcritical, low-enriched uranium solution, producing medical isotopes such as molybdenum-99 (Mo-99), iodine-131, and xenon-133 in large quantities. The neutrons are produced as a result of deuterium-tritium fusion reactions in a gas target. Isotope production, separation, and purification are performed on a weekly basis. The process is cost-effective and creates less waste than conventional production methods, while eliminating the use of highly enriched uranium.Results A facility housing eight irradiation units will be built in Janesville, WI and supply up to two-thirds of U.S. demand for Mo-99. SHINE expects to receive a construction permit from the Nuclear Regulatory Commission in late 2015 and to begin construction of its manufacturing facility in 2016.Conclusions The SHINE technology produces high-specific activity Mo-99 that is compatible with the existing supply chain. Commercial sales of medical isotopes will begin in 2018.